CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another indication of the ...

Daiichi Sankyo aims to transform its antibody-drug conjugate (ADC) leadership into a top global oncology standing. | Daiichi ...

Lilly has a long association with sports, having been a major part of the Tokyo Olympics and last month's hosting of the NCAA ...

With the program’s seventh approval in the books, the FDA is illustrating just how speedy it can be with drug reviews that ...

Daiichi Sankyo is poised to report significantly lower full-year profit for fiscal year 2025, primarily due to a 95 billion ...

President Donald Trump is set to fire FDA Commissioner Marty Makary, The Wall Street Journal reports, citing sources familiar ...

After losing the top spot in March to Johnson & Johnson’s immunology drug Tremfya, AbbVie’s rival med Skyrizi is back as the ...

With its largest-ever acquisition, Angelini gains 24-year-old Catalyst, which was listed on the Nasdaq in 2006. Catalyst ...

In an effort to reallocate resources to its growing oncology focus in the face of shrinking COVID-19 vaccine sales, German ...

Gilead raised its previous guidance of $800 million in revenues from the long-acting PrEP injectable Yeztugo based on a ...

After months of mixed messaging from the White House, the pharmaceutical industry has gained more clarity on the second Trump administration’s import tariff policy for drugs. While many of the ...

With an FDA decision date looming for its Duchenne muscular dystrophy (DMD) treatment deramiocel, Capricor Therapeutics has filed a ...